C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Enac Inhibitor Azd5634 Augments Airway Surface Liquid And Mucociliary Transport In Primary Cystic Fibrosis Airway Cells

The Cystic Fibrosis (CF) airway is dehydrated due to impaired Cl" secretion resulting from defective cystic fibrosis transmembrane conductance regulator (CFTR) function coupled with persistent Na+ absorption through the epithelial sodium channel (ENaC), which contributes to reduced mucociliary clearance. A novel ENaC inhibitor compound (AZD5634) with poor airway epithelial absorption and high affinity for ENaC has been developed, and the purpose of these studies was to evaluate its effect on airway surface liquid (ASL) and mucus transport in CF in vitro.